The deepest roots grow during the harshest storms.

MAPS reflects on the significant challenges faced during 2024, particularly the U.S. Food and Drug Administration's rejection of MDMA-assisted therapy for PTSD. This outcome is framed as a temporary setback for the broader mission of advancing psychedelic-assisted treatments. Looking toward 2025, the focus remains on resilience and future advocacy efforts. Institutional goals include preparation for Psychedelic Science 2025, as the organization continues to work toward safe and equitable access to psychedelic substances for therapeutic purposes.